LifeStance Health Group Inc (LFST) Stock Analysis

Verdict: WATCH (do not buy)

Turnaround to GAAP profitability drives upside, but massive insider and PE sponsor selling caps near-term momentum.

Investment score: 59/100

Analysis as of

Is LifeStance Health Group Inc stock worth reviewing? AI model thesis

The model assesses LFST as a Hold: operational profitability turnaround is intact, but sponsor share lockup exits and elevated valuation limit near-term upside.

7-factor investment score

LifeStance Health Group Inc opportunities and risks

What speaks for LFST

What speaks against LFST

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
LFST92.2x2.9x35.2x33.6%3.2%4.5%
CHE25.0x2.5x15.7x30.4%10.6%5.0%
RDNTn/a2.3x20.1x9.7%-0.9%-1.1%
OPCH23.4x0.8x13.8x18.2%3.7%7.5%
BLLN137.0x10.9x78.5x71.3%8.4%0.8%
CRVL33.8x3.9x19.8x23.9%11.7%2.9%
Peer median25.0x2.5x19.8x23.9%8.4%2.9%

Frequently asked questions about LifeStance Health Group Inc (LFST)

Is LFST stock a good investment?

The cached TradeMates AI model rates LifeStance Health Group Inc as WATCH (do not buy) with an investment score of 59/100. The model assesses LFST as a Hold: operational profitability turnaround is intact, but sponsor share lockup exits and elevated valuation limit near-term upside. This is algorithmic model output, not personal investment advice.

Is LFST stock a buy?

The TradeMates model verdict for LFST is WATCH (do not buy) with an investment score of 59/100. Treat this as a model signal to review, not a personal buy recommendation.